Global Single-use Bioreactors Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2035

The global Single-use Bioreactors Market is valued at USD 5.31 Billion in 2024 and is projected to reach a value of USD 31.5 billion by 2035 at a CAGR (Compound Annual Growth Rate) of 17.58% between 2025 and 2035.

The Single-use Bioreactors Market has emerged as one of the most significant advancements in bioprocessing technologies over the past decade. Single-use bioreactors (SUBs), also known as disposable bioreactors, are gaining notable traction due to their flexibility, cost-effectiveness, ease of use, and significant reduction in contamination risk. These systems are primarily used in biological processes such as cell cultivation, vaccine production, and enzyme production. What drives the market growth is the increasing demand for biologics, such as monoclonal antibodies, vaccines, and recombinant proteins. Pharmaceutical and biotechnology companies are adopting single-use systems to improve operational efficiency and reduce cleaning and validation requirements.

Furthermore, the rising prevalence of chronic diseases and the demand for personalized medicine also foster market growth. With growing biopharma investments and a shift toward advanced biomanufacturing technologies, the single-use bioreactors market is poised to expand significantly in the coming years.

Our comprehensive Single-use Bioreactors Market report is ready with the latest trends, growth opportunities, and strategic analysis- View Sample Report PDF

Market Segmentation

By Product

• Single-use Bioreactor Systems
• Single-use Media Bags
• Single-use Filtration Assemblies
• Other Products (Single-use vessels, tubing and connectors, samplers, and probes/sensor, and others)

By Type

• Stirred-tank SUBs
• Wave-induced SUBs
• Bubble-column SUBs
• Other SUBs (Hybrid bioreactors and SUBs with vertically perforated discs)

By Type of Cell

• Mammalian Cells
• Bacterial Cells
• Yeast Cells
• Other Cells (Insect and plant cells)

By Molecule Type

• Monoclonal Antibodies
• Vaccines
• Gene-modified cells
• Stem Cells
• Other Molecules (Recombinant proteins including growth factors & interferons, antisense, RNA interference and others)

By Application

• Research and Development (R&D)
• Process Development
• Bioproduction

By End User

• Pharmaceutical & Biopharmaceutical Companies
• CROs & CMOs
• Academic & Research Institutes

Market Dynamics

The single-use bioreactors market is characterized by dynamic changes influenced by technological advancements, evolving customer needs, and regulatory requirements. One of the primary drivers is the growing preference for disposable systems over traditional stainless-steel bioreactors. Unlike their reusable counterparts, SUBs significantly reduce turnaround time, cleaning and sterilization costs, and contamination risks, making them highly favorable for small- to mid-scale production.

Additionally, the COVID-19 pandemic has accelerated the demand for rapid vaccine development and production, prompting the adoption of flexible and scalable solutions like SUBs. Another crucial market driver is the increasing pipeline of biologics and the rise of personalized therapies that require adaptable, small-batch production systems

However, the market is not without its challenges. Implementation of SUBs in large-scale production and certain high-volume biologics still presents technical difficulties. Additionally, concerns around leachables and extractables from plastic components pose risks to product purity. Despite these limitations, the market continues to evolve with consistent innovation in materials and bioreactor design. Market participants are also benefiting from government initiatives and funding to bolster biomanufacturing facilities worldwide. Overall, the market dynamics are driven by a strong push toward efficiency, flexibility, and innovation in bioprocessing environments.

Market Key Players

• Sartorius Stedim Biotech (France)
• Thermo Fisher Scientific (US)
• Danaher Corporation (US)
• Merck KGaA (Germany)
• Getinge AB (Sweden)
• Eppendorf AG (Germany)
• CESCO Bioengineering (US)
• Cellexus (US)
• PBS Biotech Inc. (US)
• Distek Inc. (US)
• ABEC (US)
• Able Corporation & Biott Corporation (Japan)
• G&G Technologies Inc. (US)
• Solida Biotech GmBH (Germany)
• Satake Chemical Equipment Mfg.
• Ltd. (Japan)
• Stobbe Pharma GmBH (Germany)
• Celltainer Biotech BV (Netherlands)
• Meissner Filtration Products Inc. (US)
• bbi-biotech GmBH (Germany)
• ENDEL ENGIE (France)
• OmniBRx biotechnologies (India)
• New Horizon Biotechnology Inc. (US)
• GPC Bio (US)
• Cell culture company (US)
• Aptus bioreactors (US)

To Get a Customized List of Companies Please Click Here: https://www.vantagemarketresearch.com/singleuse-bioreactors-market-1351/request-sample

Top Trends

In recent years, the single-use bioreactors market has witnessed several transformative trends that are redefining the landscape of biomanufacturing. One of the most pronounced trends is continuous bioprocessing, where single-use systems are increasingly integrated into end-to-end continuous operations. This approach enhances productivity, reduces manufacturing footprints, and offers greater scalability and consistency. Another emerging trend is the expansion of SUBs in upstream and downstream processing, no longer limited to early-stage development but also gaining ground in commercial production.

Digitalization and the integration of automation technologies in single-use systems are also gaining momentum. Advanced sensors, monitoring capabilities, and data analytics are now commonly embedded in bioreactor systems to enhance process control and regulatory compliance. Furthermore, there is a growing push toward modular biomanufacturing, leveraging the mobility and flexibility of SUBs to enable rapid facility set-up and changes in production scale.

Additionally, the industry is witnessing the rise of customizable bioreactors tailored to specific cell lines or products, allowing for greater efficiency in development pipelines. Companies are also emphasizing sustainable materials and recyclable components to address environmental concerns, aligning with global sustainability goals. Collectively, these trends are not only shaping the future of single-use bioreactors but are also setting new benchmarks in the pharmaceutical and biotech industries for innovation, efficiency, and scalability.

Recent Developments

• In May 2025, French company eureKING acquired Skyepharma to enhance its biomanufacturing capabilities, strengthening its position in the European biologics production market and addressing the growing demand for single-use bioreactor technologies.
• In March 2024, Getinge AB launched the Single-Use Production Reactor (SUPR) system, available in 50-liter and 250-liter sizes, offering improved scalability and flexibility to meet the rising need for high-quality, single-use solutions in clinical and commercial biologics production.

Top Report Findings

• The global single-use bioreactors market is projected to reach a multi-billion dollar valuation by 2035, growing at a CAGR of over 17.58% during the forecast period.
• Biopharmaceutical companies represent the largest end-user segment, accounting for more than 45% of market revenue.
• 1000–2000L single-use bioreactors dominate in volume due to their applicability in both clinical and small-scale commercial manufacturing.
• Asia-Pacific is the fastest-growing region, while North America remains the largest market by revenue.
• Wave-induced motion and stirred-tank bioreactors are the most widely adopted types.
• Integration of AI and IoT in bioreactor monitoring is cutting time to market for several biopharmaceutical products.
• Demand for monoclonal antibodies (mAbs) and cell therapies is a major factor fueling market expansion.
• Strategic collaborations and acquisitions are shaping competitive dynamics among key players.

Challenges

While the single-use bioreactors market boasts significant growth potential, it also faces a set of challenges that industry players must navigate thoughtfully. One of the foremost concerns is the risk associated with leachables and extractables from plastic components, which can compromise the purity of the biologic product.

Regulatory agencies are increasingly scrutinizing these materials, leading to longer validation and approval timelines. Another critical limitation is the restricted application of SUBs in high-volume or large-scale biologics production, where traditional stainless-steel systems still dominate due to capacity constraints beyond the current scope of most single-use solutions.

Moreover, waste disposal and environmental sustainability remain hot-button issues, as the increased use of disposable components contributes to biomanufacturing waste, posing both ethical and regulatory challenges. Despite ongoing innovations, material compatibility, closed-system integration, and the risk of shear stress on sensitive cell cultures also restrict broader adoption. These operational and technical challenges demand a continuous focus on R&D, regulatory compliance, and process optimization.

Opportunities

Despite the challenges, the single-use bioreactors market offers vast opportunities for long-term growth and innovation. One of the most significant opportunities lies in the rising global demand for biologics and vaccines, especially in developing nations where flexible and cost-effective SUBs can enable local production capabilities.

Additionally, the increasing trend of personalized medicine and cell and gene therapies requires small-batch manufacturing with fast changeovers, making SUBs a perfect fit for these applications. Emerging markets in Asia, Latin America, and the Middle East present untapped potential for biomanufacturing infrastructure, thus expanding the geographical footprint of manufacturers.

Technological advancements in sensor integration, process analytics, and automation, as well as improved designs to accommodate large-scale production, offer further avenues for market players to innovate and differentiate.

Moreover, increased funding and partnerships between public institutions, academics, and biopharma companies are expected to propel bioprocessing innovation. All these factors, combined with rising public health awareness and investment in pandemic preparedness, present a fertile ground for continued growth in the single-use bioreactors market.

Key Questions Answered in the Keyword Report

• What is the current market size of the global single-use bioreactors market?
• What are the main drivers propelling the adoption of single-use bioreactors?
• Which types of bioreactors are leading the market in terms of usage and efficiency?
• What are the common challenges faced by manufacturers and users of single-use systems?
• How are regulatory guidelines affecting the development and deployment of SUBs?
• Which regions are experiencing the fastest growth in market adoption?
• What roles do automation and digitalization play in the evolution of SUBs?
• Who are the leading players dominating the competitive landscape of this market?

Heightened Market Interest: Our Complete Report Delivers Extensive Analysis and Trends!

https://www.vantagemarketresearch.com/industry-report/singleuse-bioreactors-market-1351

Regional Analysis: North America

North America holds the largest share in the global single-use bioreactors market, driven by robust biopharmaceutical infrastructure, significant investments in cutting-edge biotechnology, and a growing demand for high-purity biologics. The United States, in particular, is at the forefront of the market, with key pharmaceutical and biopharma companies heavily investing in automation and digitized bioprocessing technologies. Many leading players, including Thermo Fisher Scientific, Sartorius AG, and Danaher Corporation, have head offices or large production facilities in North America, giving the region a strategic advantage. The region’s regulatory landscape, though stringent, provides clear frameworks for manufacturers to innovate while maintaining compliance, fostering a competitive yet safe environment for SUB deployment.

Moreover, North America benefits from a high number of clinical trials and regulatory approvals, especially for cell and gene therapies. Government initiatives and funding focused on preparedness for infectious diseases and pandemic readiness further accelerate the adoption of flexible bioprocess systems, especially single-use bioreactors. Collaborations between biotech firms and academic research centers are frequent and contribute to a dynamic innovation pipeline. With steady investment inflows, growing public-private partnerships, and an increasing number of biologics in development and production, North America is set to maintain its dominance in the global single-use bioreactors market for the foreseeable future.